financetom
Business
financetom
/
Business
/
Coronavirus could inflict $8.8 trillion in global losses - ADB
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coronavirus could inflict $8.8 trillion in global losses - ADB
May 14, 2020 11:30 PM

MANILA (Reuters) - Global economic losses caused by the coronavirus pandemic could be between $5.8 trillion and $8.8 trillion this year, the Asian Development Bank (ADB) said on Friday, more than double its earlier estimates as containment measures paralyse economies.

Share Market Live

NSE

The ADB's forecast, equal to 6.4% to 9.7% of global gross domestic product, was worse than projections in April when it said the global economy could suffer between $2.0 trillion and $4.1 trillion in losses, depending on how long containment measures were in place.

"This new analysis presents a broad picture of the very significant potential economic impact of COVID-19," said ADB Chief Economist Yasuyuki Sawada. "It also highlights the important role policy interventions can play to help mitigate damage to economies."

The ADB said the upper end of the range assumed curbs on movement and businesses lasting six months, while the bottom end assumed they would last three months.

After the health crisis brought the economy of China, where the virus surfaced in December, to a virtual halt in the first quarter, several countries and territories have reported a rise in infections and deaths, leading to widespread travel bans and stay-at-home orders.

Nearly 300,000 people worldwide have died from complications from the virus, which has infected more than 4.3 million people.

Measures to contain the spread could inflict $1.7 trillion to $2.5 trillion in economic losses in Asia, and between $1.1 trillion and $1.6 trillion in China, the ADB said.

Travel restrictions and lockdowns will likely cut global trade by $1.7 trillion to $2.6 trillion and put between 158 million and 242 million people out of work, the ADB said.

Global central banks have moved aggressively with sweeping emergency rate cuts and fiscal stimulus measures to help combat the pandemic that jolted financial markets and stoked fears of a deep global recession.

(Reporting by Neil Jerome Morales and Karen Lema; editing by Nick Macfie)

First Published:May 15, 2020 8:30 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arizona Sonoran Reports Latest Drilling Assays Around Cactus West Pit
Arizona Sonoran Reports Latest Drilling Assays Around Cactus West Pit
Sep 16, 2024
07:27 AM EDT, 09/16/2024 (MT Newswires) -- Arizona Sonoran Copper ( ASCUF ) reported Monday drill assay results from its infill and step-out drilling program around the Cactus west pit within the Cactus project in Arizona. Highlights include 646 meters at 0.40% total copper, 643 meters at 0.31% total copper and 579 meters at 0.33% total copper. The results were...
Merck Says 10-Year Keytruda Phase 3 Trial Results Show Sustained Survival
Merck Says 10-Year Keytruda Phase 3 Trial Results Show Sustained Survival
Sep 16, 2024
07:28 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Sunday that long-term results from a phase 3 trial of Keytruda as treatment for advanced melanoma showed sustained improved survival outcomes. The 10-year overall survival rate for Keytruda was 34%, higher than 23.6% for alternative drug ipilimumab, Merck ( MRK ) said. The median OS for Keytruda-treated patients...
Bristol-Myers Squibb Reports Opdivo, Yervoy Combination's Continued Survival Benefit in Advanced Melanoma
Bristol-Myers Squibb Reports Opdivo, Yervoy Combination's Continued Survival Benefit in Advanced Melanoma
Sep 16, 2024
07:24 AM EDT, 09/16/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Sunday that 10-year follow-up data from a phase 3 trial of Opdivo monotherapy and Opdivo in combination with Yervoy in advanced or metastatic melanoma showed continued long-term survival benefit. The trial enrolled 945 patients with previously untreated advanced melanoma and after a minimum follow-up of 10 years,...
Merck Says Keytruda With Chemoradiotherapy Lowers Risk of Death in Cervical Cancer Trial
Merck Says Keytruda With Chemoradiotherapy Lowers Risk of Death in Cervical Cancer Trial
Sep 16, 2024
07:28 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Saturday that results from a phase 3 trial showed that Keytruda with chemoradiotherapy reduced the risk of death in patients newly diagnosed with high-risk locally advanced cervical cancer compared with chemoradiotherapy alone. Merck ( MRK ) said Keytruda combined with chemoradiotherapy decreased the risk of death by 33%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved